{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:14:49Z","timestamp":1790810089546,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFC2507805"],"award-info":[{"award-number":["2023YFC2507805"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425003"],"award-info":[{"award-number":["82425003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330005"],"award-info":[{"award-number":["82330005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.eclinm.2025.103229","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T01:13:44Z","timestamp":1746062024000},"page":"103229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial"],"prefix":"10.1016","volume":"83","author":[{"given":"Jinhui","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4358-3950","authenticated-orcid":false,"given":"Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zisong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"50","key":"10.1016\/j.eclinm.2025.103229_bib1","doi-asserted-by":"crossref","first-page":"25222","DOI":"10.1073\/pnas.1908576116","article-title":"Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus","volume":"116","author":"Mistry","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103229_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000239","article-title":"Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments","volume":"4","author":"Touma","year":"2017","journal-title":"Lupus Sci Med"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103229_bib3","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103229_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103229_bib5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103229_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10254","key":"10.1016\/j.eclinm.2025.103229_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103229_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103229_bib9","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103229_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103229_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2025.103229_bib12","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1182\/blood-2018-99-114434","article-title":"JWCAR029 is a CD19-targeted CAR T cell product with process and quality controls delivered as a flat dose of CAR T cell to patients with NHL","volume":"132","author":"Wang","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103229_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcyt.2022.10.011","article-title":"Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed\/refractory large B-cell lymphoma: updated results of the RELIANCE study","volume":"25","author":"Ying","year":"2023","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103229_bib15","first-page":"1400","article-title":"2019 European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103229_bib16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103229_bib17","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin's lymphoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103229_bib18","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1182\/blood-2019-127751","article-title":"Clinical response in Relapsed\/Refractory (R\/R) B-NHL treated with the CD19-directed CAR T-cell product JWCAR029","volume":"134","author":"Ying","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103229_bib19","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2018-99-115769","article-title":"Efficacy and safety of JWCAR029 in adult patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"132","author":"Yan","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103229_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103229_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan","year":"2020","journal-title":"World J Pediatr"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103229_bib22","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1093\/rheumatology\/keq269","article-title":"The management of peripheral blood cytopenias in systemic lupus erythematosus","volume":"49","author":"Hepburn","year":"2010","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103229_bib23","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated Hemophagocytic Lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"10.1016\/j.eclinm.2025.103229_bib24","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103229_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103229_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2022.153177","article-title":"Toll-like receptors in the mechanism of tributyltin-induced production of pro-inflammatory cytokines, IL-1\u03b2 and IL-6","volume":"472","author":"Alcala","year":"2022","journal-title":"Toxicology"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103229_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010080","article-title":"Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report","volume":"12","author":"Yan","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"76","key":"10.1016\/j.eclinm.2025.103229_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf0763","article-title":"EBVerified TCRs and multiple sclerosis","volume":"7","author":"Sefik","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.eclinm.2025.103229_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1110482","article-title":"CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation","volume":"14","author":"Barden","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2025.103229_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103229_bib31","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2025.103229_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103229_bib33","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:25:54Z","timestamp":1759425954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025001610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"alternative-id":["S2589537025001610"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103229","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103229"}}